DOCSLIB.ORG

The Retinoid X Receptor Agonist 9-Cis-Retinoic Acid and the 24-Hydroxylase Inhibitor Ketoconazole Increase Activity of 1,25-Dihydroxyvitamin D3 in Human Skin in Vivo

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Retinoid X Receptor Agonist 9-Cis-Retinoic Acid and the 24-Hydroxylase Inhibitor Ketoconazole Increase Activity of 1,25-Dihydroxyvitamin D3 in Human Skin in Vivo The Retinoid X Receptor Agonist 9-cis-Retinoic Acid and the 24-Hydroxylase Inhibitor Ketoconazole Increase Activity of 1,25-Dihydroxyvitamin D3 in Human Skin In Vivo Sewon Kang, Xiao-Yan Li , Elizabeth A. Duell, and Jolm J. Voorhees Department of Dermatology, U niversity o f Micltigan M edical Center Ann Arbor. Michigan. U .S .A. 1,25-Dihydroxyvitamin D 3 [1,25(OHhD31 transacti­ 1,25(OH}zD3' however, caused a synergistic increase vates its target genes via the vitamin D receptor in 24-0Hase mRNA. Similarly, 1,25(OH)2D3 plus (VDR). VDR functions in physiology as a dimer ketoconazole increased 24-0Hase mRNA synergisti­ complexed with retinoid X receptor (RXR), whose cally. Ket oconazole inhibited ex vil10 1,25(OH}zD3- natural ligand is 9-cis-retinoic acid (9-c-RA). Inacti­ induced epidermal 24-0Hase activity. Thus, 24- vation of 1,25(OH}zD3 occurs through a cytochrome OHase mRNA induction is a sensitive reporter of P-450 24-hydroxylase (OHase). The promoter of the 1,25(OH}zD3 activity ill vivo; RXR bound to VDR is human 24-0Hase gene contains a 1,25(OH)2D 3-re- not a silent partner ill vivo, because 9-c-RA enhances sponsive enhancer element (VDRE). We have used 1,25(OHhDrliganded RXRJVDR stimulation of the this VDRE containing gene as an endogenous re­ VDRE containing 24-0Hase gene; ketoconazole in­ porter for vitamin D 3-mediated gene activation ;11 hibition of 24-0Hase enhances 1,25(OH}zD3 activity vivo. Normal adult human skin was keratomed after a by impeding its breakdown. Thus, the synergistic 2-d exposure to 1,25(OHhD3' 9-c-RA, all-tl'a1ls-RA, response of human skin to topical 1,25(OH}zD3 and/or and ketoconazole. 1,25(OH}zD3 caused a concentra­ 1,25(OHhD3 analogs plus RXR retinoids and/or ke­ tion-dependent increase in 24-0Hase mRNA expres­ toconazole may be exploited to give a desired biolog­ sion as determined by northern blot analysis. The ic/therapeutic response with less 1,25(OH}zD3, mini­ activity of epidermal 24-0Hase was also induced nlizing the potential calcemic risk from systemic by 1,25(OH}zD3. Compared with vehicle, neither of absorption of 1,25(OH}zD3' KCJI words: meta.bolistll. t he RA isonlers nor ketoconazole alone induced 24- ] lUllest Del'1lwtol 108:513-518, 1997 OHase mRNA. Addition of 9-c-RA or t-RA to ,2 5-0ihydroxyvitamin D J [1,25(OHh 0 31 is a bioactive hormone nuclear rccepto r supel'family. As such, it functi ons as a hormo ne critical in seven11 cellular and phys io logic li gand (ho rmone)-dependcllt transcriptio n f.1c to r, regulating the processes. In addition to its well-established importance activatio n o f vitamin O-responsive target genes. U nlike stero id in plasma calcium ho meostasis (D oyle et al. 1972; Holick receptors that fun ction as homodimers, the V OR appears to et ai, 1972). 1.25(O H)20 3 al so affects cell prolifera tio n function predominantly as a heterodimcr (Lemo n and Freedman, a1nd di ffe re ntiation (Colston CI ai , 1981; T anaka et ai, 1982; Smith el 1996). T he heterodimeri c parmer o f VDR is retinoid X recep tor ai, 1986) , as w e ll as T-cell acti vation (Mliller and Bendtzen, 1992; ( RXl~) whosc natural li gand is 9-cis-retino ic acid (9-c-RA) (Hey- B agor et ai , 1994). The seemingly dive rse e ffects of 1.25 (O H)20 3 1113n et ai, 1992; Levin 1'1 ai, 1992) . In addition to VD R , RXR are m ainly m ediated thro ugh its intracellular vitamin 0 receptor hetcrodimerizes w ith other nuclear reccpto rs including, but not (VDR). VDR is a member of the stero id/ retinoic acidlthyro id limited to. re tinoic acid receptors (RARs) and thyroid hormone receptors. Manuscript received September 9, 1996; revised November 13, 1996; M ost of o ur current understanding o f the m o lecular m echanism accepted for publicatio n January 3, 19'1 7. b y which VDR activates its target gcnes has been through studies in T lus work was presented in part at the annual mee ting of the Society of ;f( 1I;lro system s o r in artificial ceU-transfecti on m od els. T he inheren t lnvesri gative Dermatolot;y. W ashington. Districr o f Columbia. U .S.A .. limitati ons o f these ;f( ,,;fro system s to predict ;f( 11 ;110 situations, 1996. especiall y with regard to the ro le o fRXR and its li gand in vitamin R eprint requests to: Dr. Sewon Kant;. Dcpartmcllt o f Dermato logy. D si gnaling, arc clearl y dem onstrated by inconsistent findings U niversity ofMichit;an Medical Center. ·19 10 T aubman Center. Ann Arbo r. (M acD onald cl ai, 1993; Sasaki cl ai , 1995; Kane cl ai, 1996), w h.i ch M I 48109-0314. undcrscore the necessity to directl y in vesti gate the ;f( /1 ;/10 system o f Abbreviations: (O l-l h D.l' dihydrolCyv itamin D3; (O I-l )o D, . trihydroxyvi­ ra min D,; O I-l D,. hydrolCyvitamin D, or cholecalciferol; O l-la se, hyd rox­ interest. Skin is clearly a target o rgan for 1 ,25(O H hO,1 with its cells ylase; I-RA, all-fmlls-rctino ic acid ; 9-(-RA. 9-ci.<- rctinoic acid; VDR., constitutively expressing VDRs (Berger ef ai, 1988; Milde et ai, vitamin D receptor; RX R .. retinoid X recepto r; VDR.E. vitamin D respo n­ 1991). Furthermore, certain di seases. such as ichthyosis and psori­ sive element; It AR. retin o ic acid receptor. asis. respo nd to 1,25(O H)l D, and its re lated compounds (Krag- 0022-202X/97 IS I n.S!) • Copyri ght © 1997 by The Society for In vestigative Derlllatology. Inc. 513 9 514 KANG /i'1 ti l. T H E JOUR NAL OF INVESTIGATI VE DERMATOLOGY balle, 1<)92) . PriOl' to o ur study, h o w e ve r, the re had been a lac k of nl. 19') I). e"('''pt that 36B4 rather than cycl ophilin was nsed as the control sp ecifi c m e asurable 1l1arke rs of vitamin D ac tivity in human skin ill probe. In tegrated autoradiographic intensity obtained by Ph osphorlll1ager I'iIJ() . This d e fi c ie n cy has limite d the study o f the e ffects and lo r th e 24-01-/ase gene was lirst di vid ed by that of the control gell e (3 6B4). The divisio n produc t" was then divided ag ain b y t'h ~ l t o f the contro l tre~ltlll e llt m o lecular si g naling o f these m o lecules in human sk in ;11 1';1'0. for relative cOl11pa risons. Beca use the nC[;ative ('o ntrol (vehicle) group 24-Hydro'-'Y lase (O Hase) is a cytochro m e P-4 50 e n z yl1l e tha t contained many sl11all nU111bers, including zero. which precillded the hydro x ylates 1,2S(O H h D at: the 24 p osition, resulting in a m e ­ J require d CO lllptltatio n s (divisio n b y zero), data arc e xpressed as pe rcen t tabo li te. 1.24.25-trihydroxyvitilmin D:\ 1.1. 24,2 S(O H)}D }J. with a inducti on of thc positive control (1).05% I ,25 (0 1-l),D, ). which was consid­ m arke dly re duced ac ti v ity (Ho li ck ('/ ,Ii. J 9 73; O h yama and Okuda, e r ed Inaxil1lll1ll induc t-jo n . 1( 91). R,ecent c loning o f this gene hil S reveal e d that its natural Measurement of 24-0Hase Enzytne Ac tivity HUl11an skin trcared pro m o te r harbo rs vitamin D resp o n sive e le m ents (YD IU ) that are with vehiclc and 0.05% 1. 25(0 1-l ),D , lor 2 d under continuous occiusiolJ composed o f AGGTCA- like hexameric direct re p eats separate d b y w as kcrato nlc-biopsicd . T he biopsy specinlCl1 s we re incubated in trypsin 3-bp-a so calJ e d DR3 (Ohyama el ai, 1994; Zierold cl ai , 1995). (0 .1 % in solution consisting of 30 mM I-IE PES buffer, 10 111M glu cose. 3 mM This type (DR3) of e nhancer c le m e nt has also b een identified in KC I. 130 111M NaC I. and I 111M sodium phosphate. 1'1-1 7,2) ('or 30 min at o ste o calcin and calbindin D ~K gen es (Ke rne r £'1 ai , 1989; D arwish 35°C to separate thl' epidermis &om the dennis. Dispersed epidermal cell s and D eLuca, 1992) '\I1d appe ars to be the physiologic ally relevant were centrifuged at 2000 X .~ lo r 5 l11in . Thc pell eted cell s were resuspcnded YDRE. A lthoug h some reports of VDR- YDR h o modil1'1 e rs bind­ in 5 ~111 o f 0. 1% trypsin inhibitor and then centrifuged again at 2000 X g for ing to VDR.E exist (C arlbe rg 1'1 (/1 , 1993), prevailing evide n ce p o ints 5 111n1.
Load more

Recommended publications
  • Detailed Review Paper on Retinoid Pathway Signalling
    1 1 Detailed Review Paper on Retinoid Pathway Signalling 2 December 2020 3 2 4 Foreword 5 1. Project 4.97 to develop a Detailed Review Paper (DRP) on the Retinoid System 6 was added to the Test Guidelines Programme work plan in 2015. The project was 7 originally proposed by Sweden and the European Commission later joined the project as 8 a co-lead. In 2019, the OECD Secretariat was added to coordinate input from expert 9 consultants. The initial objectives of the project were to: 10 draft a review of the biology of retinoid signalling pathway, 11 describe retinoid-mediated effects on various organ systems, 12 identify relevant retinoid in vitro and ex vivo assays that measure mechanistic 13 effects of chemicals for development, and 14 Identify in vivo endpoints that could be added to existing test guidelines to 15 identify chemical effects on retinoid pathway signalling. 16 2. This DRP is intended to expand the recommendations for the retinoid pathway 17 included in the OECD Detailed Review Paper on the State of the Science on Novel In 18 vitro and In vivo Screening and Testing Methods and Endpoints for Evaluating 19 Endocrine Disruptors (DRP No 178). The retinoid signalling pathway was one of seven 20 endocrine pathways considered to be susceptible to environmental endocrine disruption 21 and for which relevant endpoints could be measured in new or existing OECD Test 22 Guidelines for evaluating endocrine disruption. Due to the complexity of retinoid 23 signalling across multiple organ systems, this effort was foreseen as a multi-step process.
    [Show full text]
  • Liarozole Hydrochloride (BANM, USAN, Rinnm) Kinetin Hidrocloruro De Liarozol; Liarozole, Chlorhydrate De; Liarozoli 1
    Isotretinoin/Liarozole 1603 Malignant neoplasms. Retinoids such as isotretinoin have 9. Matthay KK, et al. Treatment of high-risk neuroblastoma with Profile been studied in the treatment of various neoplastic or preneoplas- intensive chemotherapy, radiotherapy, autologous bone marrow Kinetin is a plant growth hormone that has been promoted in transplantation, and 13-cis-retinoic acid. N Engl J Med 1999; tic disorders. Although oral tretinoin is used for remission induc- 341: 1165–73. products for the management of photodamaged skin and hyper- tion in acute promyelocytic leukaemia (see p.1619), other retin- 10. Kohler JA, et al. A randomized trial of 13-cis retinoic acid in pigmentation but good evidence of efficacy appears to be lack- oids do not have an established role in the treatment of cancer. children with advanced neuroblastoma after high-dose therapy. ing. There may, however, be a place for the use of retinoids in the Br J Cancer 2000; 83: 1124–7. Preparations chemoprevention of some malignancies. Skin disorders. Apart from its established role in the treatment Proprietary Preparations (details are given in Part 3) There has been particular interest in the potential for retinoids to of acne (above), isotretinoin has been tried in many other skin Arg.: Kinerase†; Braz.: Kinerase; Hong Kong: Kinerase; Malaysia: Kin- prevent the formation of skin cancers (p.672) in patients at in- disorders not responding to usual therapy.1,2 Clinical responses to erase†; Mex.: Kinerase; Singapore: Kinerase; USA: Kinerase. creased risk. Maintenance immunosuppression may increase the oral isotretinoin have been reported1 in small numbers of patients incidence of pre-malignant and malignant skin lesions in solid with anogenital warts (p.1584), rosacea (p.1583), and lichen pla- organ transplant recipients; large numbers of lesions can develop nus (p.1580).
    [Show full text]
  • Progress Towards Genetic and Pharmacological Therapies for Keratin Genodermatoses: Current Perspective and Future Promise
    15 March 2005 Use of Articles in the Pachyonychia Congenita Bibliography The articles in the PC Bibliography may be restricted by copyright laws. These have been made available to you by PC Project for the exclusive use in teaching, scholar- ship or research regarding Pachyonychia Congenita. To the best of our understanding, in supplying this material to you we have followed the guidelines of Sec 107 regarding fair use of copyright materials. That section reads as follows: Sec. 107. - Limitations on exclusive rights: Fair use Notwithstanding the provisions of sections 106 and 106A, the fair use of a copyrighted work, including such use by reproduction in copies or phonorecords or by any other means specified by that section, for purposes such as criticism, comment, news reporting, teaching (including multiple copies for classroom use), scholarship, or research, is not an infringement of copyright. In determining whether the use made of a work in any particular case is a fair use the factors to be considered shall include - (1) the purpose and character of the use, including whether such use is of a commercial nature or is for nonprofit educational purposes; (2) the nature of the copyrighted work; (3) the amount and substantiality of the portion used in relation to the copyrighted work as a whole; and (4) the effect of the use upon the potential market for or value of the copyrighted work. The fact that a work is unpublished shall not itself bar a finding of fair use if such finding is made upon consideration of all the above factors.
    [Show full text]
  • Robert Foti to Cite This Version
    Characterization of xenobiotic substrates and inhibitors of CYP26A1, CYP26B1 and CYP26C1 using computational modeling and in vitro analyses Robert Foti To cite this version: Robert Foti. Characterization of xenobiotic substrates and inhibitors of CYP26A1, CYP26B1 and CYP26C1 using computational modeling and in vitro analyses. Agricultural sciences. Université Nice Sophia Antipolis, 2016. English. NNT : 2016NICE4033. tel-01376678 HAL Id: tel-01376678 https://tel.archives-ouvertes.fr/tel-01376678 Submitted on 5 Oct 2016 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Université de Nice-Sophia Antipolis Thèse pour obtenir le grade de DOCTEUR DE L’UNIVERSITE NICE SOPHIA ANTIPOLIS Spécialité : Interactions Moléculaires et Cellulaires Ecole Doctorale : Sciences de la Vie et de la Santé (SVS) Caractérisation des substrats xénobiotiques et des inhibiteurs des cytochromes CYP26A1, CYP26B1 et CYP26C1 par modélisation moléculaire et études in vitro présentée et soutenue publiquement par Robert S. Foti Le 4 Juillet 2016 Membres du jury Dr. Danièle Werck-Reichhart Rapporteur Dr. Philippe Roche Rapporteur Pr. Serge Antonczak Examinateur Dr. Philippe Breton Examinateur Pr. Philippe Diaz Examinateur Dr. Dominique Douguet Directrice de thèse 1 1. Table of Contents 1. Table of Contents ..............................................................................................................................
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Study on Cytochrome P-450 Dependent Retinoic Acid Metabolism and Its Inhibitors As Potential Agents for Cancer Therapy
    Sci Pharm www.scipharm.at Research article Open Access Study on Cytochrome P-450 Dependent Retinoic Acid Metabolism and its Inhibitors as Potential Agents for Cancer Therapy Mobasher AHMAD University College of Pharmacy, University of the Punjab (Old Campus), the Mall, Lahore, Pakistan. E-mail: [email protected] Sci Pharm. 2011; 79: 921–935 doi:10.3797/scipharm.1106-18 Published: August 12th 2011 Received: June 24th 2011 Accepted: August 12th 2011 This article is available from: http://dx.doi.org/10.3797/scipharm.1106-18 © Ahmad; licensee Österreichische Apotheker-Verlagsgesellschaft m. b. H., Vienna, Austria. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract The relative lack of clinical success with conventional anticancer agents may be due in part to the traditional concept of cancer being a biological state rather than a dynamic process. Redefining cancer as a dynamic disease commencing with carcinogenesis introduces the possibility of chemoprevention. Retinoids offer the promise of a therapeutic option based on differentiation of premalignant as well as malignant cells. Research to date has concentrated on the use of exogenous retinoids in cancer. Although this research continues with new retinoid derivatives, an alternative approach to overcoming the drawbacks associated with exogenous retinoids has been to increase the levels of endogenous retinoic acid (RA) by inhibiting the cytochrome P450- mediated catabolism of RA using a novel class of agents known as retinoic acid metabolism blocking agents (RAMBAs which increase the level of endogenous retinoic acid (RA) within the tumor cells by blocking their metabolism.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0177609 A1 Swindell Et Al
    US 2002O177609A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0177609 A1 Swindell et al. (43) Pub. Date: Nov. 28, 2002 (54) FATTY ALCOHOL DRUG CONJUGATES Related U.S. Application Data (60) Provisional application No. 60/278,457, filed on Mar. (76) Inventors: Charles S. Swindell, Merion, PA (US); 23, 2001. Glenn J. Fegley, Eagleville, PA (US) Publication Classification Correspondence Address: (51) Int. Cl." ..................... A61K 31/4453; A61K 31/40; Edward R. Gates, Esq. A61K 31/15 Chantal Morgan D'Apuzzo (52) U.S. Cl. ......................... 514/329; 514/426; 514/640; Wolf, Greenfield & Sacks, P.C. 546/244; 548/558; 564/256 600 Atlantic Ave Boston, MA 02210 (US) (57) ABSTRACT The invention provides conjugates of fatty alcohols and (21)21) AppAppl. No.: 10/107,537/107, p harmaceutical agents9. useful in treating9. cancer, Viruses, psychiatric disorders. Compositions, pharmaceutical prepa rations, and methods of preparation of the fatty alcohols 22) Filled: Mar. 25, 2002 p harmaceutical agent9. coniugatesJug are pprovided. US 2002/0177609 A1 Nov. 28, 2002 FATTY ALCOHOL DRUG CONJUGATES was observed (for an adenosine receptor agonist), and it was postulated that the pendant lipid molecule interacted with RELATED APPLICATION the phospholipid membrane to act as a distal anchor for the 0001. This application claims priority under 35 U.S.C. S receptor ligand in the membrane micro environment of the 119 (e) from U.S. provisional patent application Serial No. receptor. This increase in potency, however, was not 60/278,457, filed on Mar. 23, 2001, entitled Fatty Alcohol observed when the same lipid derivatives of adenosine Drug Conjugates.
    [Show full text]
  • Clinical Study of 9-Cis Retinoic Acid
    Leukemia (1998) 12, 1518–1521 1998 Stockton Press All rights reserved 0887-6924/98 $12.00 http://www.stockton-press.co.uk/leu Clinical study of 9-cis retinoic acid (LGD1057) in acute promyelocytic leukemia SL Soignet1, F Benedetti1, A Fleischauer1, BA Parker2, JA Truglia2, M Ra Crisp2 and RP Warrell Jr1 1Developmental Chemotherapy and Leukemia Services, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and the Cornell University Medical College, New York, NY; and 2Ligand Pharmaceuticals Inc. San Diego, CA, USA The use of all-trans retinoic acid (RA) for remission induction some proliferation-associated proteins.14–17 Whereas all-trans markedly increases survival of patients with acute promyelo- RA binds only RARs, 9-cis RA binds and activates both RARs cytic leukemia (APL) compared to patients treated solely with 18–20 cytotoxic chemotherapy. However, clinical resistance to this and RXRs. Preclinical studies also showed that 9-cis agent develops rapidly, which has been associated with a pro- RA was more potent than all-trans RA in inducing myeloid gressive decline in plasma drug concentrations. Previous stud- differentiation in HL60 cells.21,22 ies suggested that 9-cis RA, a retinoid receptor ‘pan agonist’ In a preliminary report, we found that 9-cis RA could did not induce its own catabolism to the same extent as all- induce complete remission in APL, but the drug did not trans RA. Therefore, we conducted a dose-ranging study of this appear capable of reversing clinically acquired retinoid resist- compound in patients with both relapsed and newly diagnosed 23 APL. We treated 18 patients with morphologically diagnosed ance.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Study on the Latest Research Trends in Natural Products with Anti-Aging Effects
    Journal of Convergence for Information Technology e-ISSN 2586-4440 Vol. 9. No. 12, pp. 286-293, 2019 DOI : https://doi.org/10.22156/CS4SMB.2019.9.12.286 A Study on the Latest Research Trends in Natural products with Anti-Aging Effects Young-Hee Pyo1, Seon-Hee You2* 1Professor, Dept. of Beauty & Cosmetic, Osan University 2Adjunct professor, Dept. of Beauty Stylist-Major in Skin Care, Yeonsung University 항노화 효능을 가진 천연물에 대한 최신 연구 동향에 관한 연구 표영희1, 유선희2* 1오산대학교 뷰티&코스메틱계열 교수, 2연성대학교 뷰티스타일리스트과 겸임교수 Abstract In this study, four types of retinol, retinyl palmitate, adenocin, and polytoxylate-dretinamide, which are the ingredients of the Ministry of Food and Drug Safety Notice, included in the study. also we looked at trends in research on Sciadopitys verticillata, Prunella vulgaris, Celosia cristata L., Brazilin, Persicaria hydropiper, Astragalus membranaceus Bunge, Forsythiae Fructus, Lithospermum root, Rheum undulatum L. and Cistanche deserticola Y. C. Ma a natural material that has the efficacy of antioxidant aging. The anti-aging study so far has been found to be centered mainly on collagen production and elastase synthesis inhibition mechanisms. However, given that the aging process of the skin is caused by various ageing processes, it is believed that anti-aging studies using safe and effective natural materials that can help the skin age with various mechanisms should be conducted. Key Words : Anti-aging, Ministry of Food and Drug Safety, Elastase, Wrinkle Improvement, Natural Materials, Collagen 요 약 본 연구에서는 식약청 고시 원료인 레티놀, 레티닐팔미테이트, 아데노신, 폴리에톡실레이티드레틴아마이드 4종류와 항 노화의 효능을 가진 천연 원료인 금송, 하고초, 맨드라미, 브라질린, 여뀌, 황기, 연교, 자근, 대황, 육종 용에 대한 연구 동향을 살펴보았다.
    [Show full text]
  • Liarozole and 13-C/S-Retinoic Acid Anti-Prostatic Tumor Activity
    ICANCT:RRI:SI:ARCHs.i..107.1-3077.Julyi. i Liarozole and 13-c/s-Retinoic Acid Anti-Prostatic Tumor Activity M. E. Stearns,1 M. Wang, and K. Fudge Department i>fPathology. Medical College <>/'Pennsylvania, Philadelphia. Pennsylvania I'VI29 ABSTRACT metastasizing PC-3 subclone (6). termed PC-3 ML-B-. we have in Liarozole f'umarate (R85.246), a novel benzimidazole derivative, re vestigated drug effects («)on processes important for invasion in vitm (i.e., adherence, chemotactic response, collagenase IV secretion); and duced S.C. and bone metastasis tumor growth by the androgen-indcpen- dent PC-3MI--B2 human prostatic carcinoma clone in SCII) mice. The (/>) on tumor growth and survival s.c. and in bone marrow métastases utilizing a SCID mouse model developed in our laboratory (6). Taken drug inhibited cell invasion of Matrigel in Boyden chamber chemotactic together, the data demonstrated that liarozole is an effective antilum- assays and the secretion of type IV collagenase. In vitro, liarozole failed to inhibit cell proliferation and cell attachment to various substrates (Matri- origenic agent for the treatment of prostate tumor growth and for gel, laminili, type IV collagen, and fibronectin). In vivo, the drug also prevention of tumor metastasis. blocked type IV collagenase production in established s.c. tumors. Liaro zole has been postulated by others (R. De Coster, VV.Wouters, R. Van MATERIALS AND METHODS Ginckel. D. End. el al. J. Steroid Biochem. Mol. Biol., 43: 197-201. 1992) to inhibit retinole acid catabolism. Our data indicate that liarozole treat For cell culture PC-3 ML-B- cells, a highly invasive, bone-metastasizing ment can increase the tumor retinoic acid levels in vivo.
    [Show full text]
  • Nuclear Receptors Product Listing | Edition 2
    Nuclear Receptors Product Listing | Edition 2 Kudzu Pueraria lobata A source of Daidzein Nuclear Receptor Products by Group: • Steroid Hormone Receptor Group • Thyroid Hormone Receptor-like Group • Retinoid X Receptor-like Group • Steroidogenic Factor-like Group Tocris Product Listing Series Contents This listing contains over 150 products from Tocris, including a wide range of nuclear receptor agonists and antagonists available for each nuclear receptor group. Related products are also listed, alongside a selection of relevant scientific literature available from www.tocris.com. Introduction................................................................................... 3 Thyroid Hormone Receptor-like Group (continued) Pregnane X Receptor (PXR) ................................................. 9 Steroid Hormone Receptor Group ........................................... 5 Retinoic Acid Receptors (RAR)......................................... 10 Androgen Receptor (AR) ...................................................... 5 Rev-Erb Receptors ............................................................... 11 Estrogen Receptors (ER) ...................................................... 5 Thyroid Hormone Receptors (TR) .................................... 11 Estrogen-related Receptors (ERR) ..................................... 7 Vitamin D Receptor (VDR) ................................................. 11 ............................................. Glucocorticoid Receptor (GR) 7 Retinoid X Receptor-like Group ...........................................
    [Show full text]